Healthy ChildrenNCT04639830
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
An observational study of Healthy Children and Children With Neurodevelopmental Disorders, run by National Institute of Mental Health (NIMH) at 1 site in United States.
Trial summary
Background: During the first few decades of life, the brain changes dramatically in shape and function. Sleep lets researchers measure these changes. Researchers want to create a database of sleep and neurodevelopmental data in a group of infants and children to learn more. Read more about this study
- Who is it for?
- Ages 6 months to 8 years
- Conditions the study is for
- Healthy Children, Children With Neurodevelopmental Disorders, Children With Neuropsychiatric Disorders
- How many people
- 58 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2021to 15 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 8 years
- All sexes
- No healthy volunteers
- Child
Study population: Study Population: The total number of participants to be enrolled will be set at N = 244 (6 months to 8 years old) and will include the following: 1) Study 1: N = 90 with no known risk for neurodevelopmental disorders. These include children without identified neurodevelopmental problems who score within age-expected ranges on cognitive and behavioral screeners. 2) Study 2: N = 154 children at risk for or known to have selected neurodevelopmental/neuropsychiatric disorders, based on any one or more of the following criteria: a) Enrolled in early intervention b) Getting any targeted therapies c) Neurodevelopmental or neuropsychiatric disorder d) Failed Infant Toddler Checklist (ITC) (ages 6 months 24 months) e) Failed the Early Intervention (EI) screener (>24 months)
Who may be able to join
- -Consent: Parent/caregiver (legal guardian) can give consent. NIH employees children are eligible to participate with the exception of NIMH employees children.
- Comments: Parents will provide consent for all minors. Verbal assent will be obtained from minors 7 years and older when applicable.
- The child is between 6 months \& 76 months at the time of enrollment for the main study.
- Comments: Prescreening assessment
- -Apnea hypopnea index (AHI) < 2/hour and no other evidence of sleep disordered breathing (SDB)
- -Consent: Parent/caregiver (legal guardian) can give consent. NIH employees children are eligible to participate with the exception of NIMH employees children.
Show all 18Show fewer
- Comments: Parents will provide consent for all minors. Verbal assent will be obtained from minors 7 years and older when applicable.
- -The child is between 6 months \& 76 months at the time of enrollment for the main study.
- Comments: Screening assessment
- -The child meets any one or more of the following:
- Enrolled in early intervention
- Getting any targeted therapies
- Neurodevelopmental or neuropsychiatric disorder
- Failed ITC (ages 6 months - 24 months)
- Failed the EI screener (>24 months)
- Child s first degree relative has been diagnosed with a neurodevelopmental disorder, such as autism or schizophrenia, or severe mental illness, such as major depressive disorder or bipolar disorder
- Comments: Screening assessment
- Apnea hypopnea index (AHI) <= 2/hour and no other evidence of sleep disordered breathing (SDB)
Who cannot join
- -Meets inclusion criteria for Group B (known risk)
- Comments: Screening assessment
- -Any chronic or acute medical condition severe enough to interfere with overnight sleep study acquisition, such as a tracheotomy, uncontrolled seizure disorder, or ventilator dependency, or history of stroke or major neurologic insult. Taking any medications that is known to change sleep parameters within 2 weeks of screening polysomnogram.
- Comments: Screening assessment: Medical history
- -Any history of early intervention or diagnosis of a condition that put the child at risk for neurodevelopmental problems (e.g., genetic disorder, prenatal exposures, extreme prematurity)
- Screening assessment: Medical history
Show all 19Show fewer
- Primary language other than English in the home
- Comments: Screening assessment
- -Apnea hypopnea index (AHI) >2/hr or any other evidence of sleep disordered breathing (SDB)
- The children of NIMH employees and staff may not take part.
- Comments: Screening assessment
- -Any chronic or acute medical condition severe enough to interfere with completion overnight sleep study acquisition, such as a tracheotomy, uncontrolled seizure disorder, or ventilator dependency.
- Comments: Screening assessment: Medical history
- -Primary language other than English in the home
- Comments: Screening assessment
- -Diagnosed with any of the following common genetic disorders associated with intellectual impairment: Fragile X, Down Syndrome, PraderWilli, Rett, Angelman, Phelan -McDermid, Smith-Lemli-Opitz, identified with a disorders of autonomic dysfunction that might compromise breathing function (examples include congenital central hypoventilation syndrome, familial dysautonmia), disorders of skeletal deformities (Marfan, achondroplasia), a neurogenic condition (spinal muscular atrophy, Duchenne muscular dystrophy, myotonic dystrophy), congenital myopathies or storage diseases (mucopolysaccharidosis, NCL, Wilsons, etc.)
- -The children of NIMH employees and staff may not take part.
- Comments: Screening assessment
- -Apnea hypopnea index > 2/hr or any other evidence of sleep disordered breathing (SDB)
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
About this study
Background:
During the first few decades of life, the brain changes dramatically in shape and function. Sleep lets researchers measure these changes. Researchers want to create a database of sleep and neurodevelopmental data in a group of infants and children to learn more.
Read more
Objective:
To address a knowledge and data gap in the field of sleep and neurodevelopment in infants and children.
Eligibility:
Children ages 6 months to 76 months who may or may not be at risk for neurodevelopmental and neuropsychiatric disorders. Also, children ages 6 months to 8 years who have a referral for a sleep study.
Design:
Participants will have neurodevelopmental testing. They will have a medical, psychiatric, and family history. They will have a physical and neurological exam. They will be interviewed and complete surveys. They will give a cheek swab and/or blood sample.
Some participants will have 1 study visit that lasts 2 days.
Other participants will have up to 4 study visits. Each visit will last 2 days. Visits occur every 8 months to 1 year, for a total participation time of 2 years.
Participants will have a 20-minute daytime electroencephalogram (EEG), if possible. This EEG session will be used to calibrate the machine for the overnight study.
Participants will take part in an inpatient overnight sleep study. Electrodes will be placed on the participants. For young children, parents will help place the EEG leads. Other sensors may also be placed. A gauze cap will be placed on participants head to protect the leads and keep the participants from moving them. 'Lights out' will occur as close to participants bedtime as possible.
Read the detailed description
This is a multisite longitudinal study with NIH as the lead site. The other sites: Texas Children s Hospital, Boston Children s Hospital, Geisinger Medical Center, NYU and the NHLBI- supported, area specific repository, National Sleep Research Repository (NSRR). This study will address the data gap established by two NIMH sponsored intramural/extramural workshops (2017 and 2018) in the field of sleep and neurodevelopment by establishing a standardized, reliable protocol for real time acquisition of research data on the normal and abnormal neuro-maturational changes that are sleep-dependent. It will facilitate data-sharing in this area and speed the pace of discovery. Sleep EEG is a highly advantageous modality to provide non-invasive, reliable, robust and reproducible imaging of the brain in young and neurodevelopmentally disordered populations. Sleep EEG affords data acquisition of functional network microstructure with a decreased signal to noise ratio compared to acquisition in the awake state. In addition, potential deviations from the natural ultradian and other sleep oscillatory patterns of the sleep process have the potential to inform on underlying developing neuropathology of various microstructures and neurotransmitter systems prior to the emergence of putatively associated behavioral phenomenon. Ideally, these oscillatory trajectories will not only map to developmental behavioral phenotypes but also to clinical disorders of the sleep state itself, such as the malignant insomnias that are prevalent in neuropsychiatric and neurodevelopmental syndromes. The protocol will initiate the establishment of a normative database for electrophysiologic sleep data in the developing brain. Disorders of particular interest include autism, disorders of social cognition and other neurodevelopmental disorders, childhood psychiatric disorders, and unique clinical presentations of neurogenetic syndromes, such as those associated with genetic disorders or those with a unique family history. The study plans to use a quantitative, dimensional approach to outcome measurement with respect to adaptive functioning in children and to symptoms of behavioral and/or neurodevelopmental problems, irrespective of diagnosis.
While specific differences in the architecture of sleep (e.g., stages, movement abnormalities, cyclicity, spindles and other bio-signatures that reflect anatomical microstructure) may be used to differentiate neurodevelopmental cohorts, the enormous potential of this proposed database lies in the ability to track functional connectivity (coherence) during sleep in the developing brain in a longitudinal, prospective manner, thereby establishing both normal and aberrant trajectories. Predictive relationships can be determined once these trajectories are established. Coherence studies would allow for the potential recreation of neural circuits that sub-serve various brain functions, such as language and attention. Tracking the trajectory of neural development prior to and during the developmental window when these circuits are maturing will allow for an understanding of best potential windows of intervention.
Objectives: The long term, primary objective of this protocol is to evaluate the degree to which the development and maturation of sleep patterns, with an emphasis on the relationship of those patterns to electrophysiologic signals, can predict cognitive and behavioral outcomes. Assessing participants over time will allow researchers to gain additional knowledge about the role of abnormal sleep, measured both clinically and by polysomnogram, in various childhood neuropsychiatric/ neurodevelopmental disorders and behavioral syndromes.
Study Population: The total number of participants to be enrolled will be set at N = 244 (6 months to 8 years old) and will include the following:
- Study 1: N = 90 with no known risk for neurodevelopmental disorders. These include children without identified neurodevelopmental problems who score within age-expected ranges on cognitive and behavioral screeners.
- Study 2: N = 154 children at risk for or known to have selected neurodevelopmental/neuropsychiatric disorders, based on any one or more of the following criteria:
- Enrolled in early intervention
- Getting any targeted therapies
- Neurodevelopmental or neuropsychiatric disorder
- Failed Infant Toddler Checklist (ITC) (ages 6 months 24 months)
- Failed the Early Intervention (EI) screener (>24 months)
Design: Study 1 (N = 90) and Study 2 (N = 154) use the same accelerated longitudinal design.
Outcome Measures: The primary outcome measure in Study 1 is sleep spindle activity. Study 2 has an additional primary outcome, the Vineland Adaptive Behavior (VABS) Socialization growth scale. In both studies, secondary outcome measures will include:other characteristics of sleep spindles, sleep rhythms (ultradian, circadian), macroarchitecture (stages and latencies), microarchitecture (measures of connectivity and network analyses).
Predictors include other neurodevelopmental variables, including other domain scores from the Vineland, IQ, and quantitative measurement of behavioral problems and social communicative development.
- Conditions
- Healthy Children, Children With Neurodevelopmental Disorders, Children With Neuropsychiatric Disorders, Children With Behavioral Syndromes
- Keywords
- SLEEP STUDY, Healthy Children, Neurogenetic Syndrome, Abnormal Neurodevelopment, EEG, Natural History
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children with a known risk | Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder. | |
| Children with no known risk | Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sleep Spindle Activity
The primary outcome measure in Study 1 is sleep spindle activity. Study 2 has an additional primary outcome, the Vineland Adaptive Behavior (VABS) Socialization growth scale.
Measured: ongoing
Vineland Adaptive Behavior (VABS) Socialization growth scale.
The primary outcome measure in Study 1 is sleep spindle activity. Study 2 has an additional primary outcome, the Vineland Adaptive Behavior (VABS) Socialization growth scale.
Measured: ongoing
Secondary outcomes (1)
Sleep Spindle Characteristics
Secondary outcome measures will include: other characteristics of sleep spindles, sleep rhythms (ultradian, circadian), macroarchitecture (stages and latencies), microarchitecture (measures of connectivity and network analyses).
Measured: ongoing
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Nov 2020
- Study start9 Nov 2021
- Primary completion15 Apr 2027 (estimated)
- Study completion15 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy ChildrenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 58 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Ashura W Buckley, M.D., Principal investigator, National Institute of Mental Health (NIMH)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04639830
- Sponsor's protocol ID
- 200166
- Other IDs
- 20-M-0166
- Status last verified
- 6 Oct 2026
- First submitted
- 20 Nov 2020
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will use the National Sleep Research Resource (NSRR), based at Brigham and Women s Hospital, as a comprehensive data repository for the visualization, query, and analysis of sleep EEG and related physiologic parameters, neurodevelopmental and demographic data. Most medical and sleep data will be stored using NSRR. All data shared with NSRR will be coded. Samples and data for genomic analyses will be shared with Baylor College of Medicine and they will also be shared with the NIMH Repository \& Genomics Resource (NRGR). Coded data from this study for all child participants will also be submitted to the NIH sponsored National Database for Autism Research (NDAR). Data and samples may also be shared with collaborating laboratories at NIH or outside of NIH and/or submitted to NIH-designated repositories and databases if consent for sharing was obtained. Repositories receiving data and/or samples from this protocol may be open-access or restricted access.
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
- ClinicalTrials.gov ID
- NCT04639830
- Acronym / sponsor ID
- 200166
- Conditions
- Healthy Children, Children With Neurodevelopmental Disorders, Children With Neuropsychiatric Disorders, Children With Behavioral Syndromes
- Keywords
- SLEEP STUDY, Healthy Children, Neurogenetic Syndrome, Abnormal Neurodevelopment, EEG, Natural History
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 58 participants (actual)
- Lead sponsor
- National Institute of Mental Health (NIMH)US National Institutes of Health
- Study start
- 9 Nov 2021 (actual)
- Primary completion
- 15 Apr 2027 (estimated)
- Study completion
- 15 Apr 2027 (estimated)
- First posted
- 23 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
During the first few decades of life, the brain changes dramatically in shape and function. Sleep lets researchers measure these changes. Researchers want to create a database of sleep and neurodevelopmental data in a group of infants and children to learn more.
Objective:
To address a knowledge and data gap in the field of sleep and neurodevelopment in infants and children.
Eligibility:
Children ages 6 months to 76 months who may or may not be at risk for neurodevelopmental and neuropsychiatric disorders. Also, children ages 6 months to 8 years who have a referral for a sleep study.
Design:
Participants will have neurodevelopmental testing. They will have a medical, psychiatric, and family history. They will have a physical and neurological exam. They will be interviewed and complete surveys. They will give a cheek swab and/or blood sample.
Some participants will have 1 study visit that lasts 2 days.
Other participants will have up to 4 study visits. Each visit will last 2 days. Visits occur every 8 months to 1 year, for a total participation time of 2 years.
Participants will have a 20-minute daytime electroencephalogram (EEG), if possible. This EEG session will be used to calibrate the machine for the overnight study.
Participants will take part in an inpatient overnight sleep study. Electrodes will be placed on the participants. For young children, parents will help place the EEG leads. Other sensors may also be placed. A gauze cap will be placed on participants head to protect the leads and keep the participants from moving them. 'Lights out' will occur as close to participants bedtime as possible.
Detailed description
This is a multisite longitudinal study with NIH as the lead site. The other sites: Texas Children s Hospital, Boston Children s Hospital, Geisinger Medical Center, NYU and the NHLBI- supported, area specific repository, National Sleep Research Repository (NSRR). This study will address the data gap established by two NIMH sponsored intramural/extramural workshops (2017 and 2018) in the field of sleep and neurodevelopment by establishing a standardized, reliable protocol for real time acquisition of research data on the normal and abnormal neuro-maturational changes that are sleep-dependent. It will facilitate data-sharing in this area and speed the pace of discovery. Sleep EEG is a highly advantageous modality to provide non-invasive, reliable, robust and reproducible imaging of the brain in young and neurodevelopmentally disordered populations. Sleep EEG affords data acquisition of functional network microstructure with a decreased signal to noise ratio compared to acquisition in the awake state. In addition, potential deviations from the natural ultradian and other sleep oscillatory patterns of the sleep process have the potential to inform on underlying developing neuropathology of various microstructures and neurotransmitter systems prior to the emergence of putatively associated behavioral phenomenon. Ideally, these oscillatory trajectories will not only map to developmental behavioral phenotypes but also to clinical disorders of the sleep state itself, such as the malignant insomnias that are prevalent in neuropsychiatric and neurodevelopmental syndromes. The protocol will initiate the establishment of a normative database for electrophysiologic sleep data in the developing brain. Disorders of particular interest include autism, disorders of social cognition and other neurodevelopmental disorders, childhood psychiatric disorders, and unique clinical presentations of neurogenetic syndromes, such as those associated with genetic disorders or those with a unique family history. The study plans to use a quantitative, dimensional approach to outcome measurement with respect to adaptive functioning in children and to symptoms of behavioral and/or neurodevelopmental problems, irrespective of diagnosis.
While specific differences in the architecture of sleep (e.g., stages, movement abnormalities, cyclicity, spindles and other bio-signatures that reflect anatomical microstructure) may be used to differentiate neurodevelopmental cohorts, the enormous potential of this proposed database lies in the ability to track functional connectivity (coherence) during sleep in the developing brain in a longitudinal, prospective manner, thereby establishing both normal and aberrant trajectories. Predictive relationships can be determined once these trajectories are established. Coherence studies would allow for the potential recreation of neural circuits that sub-serve various brain functions, such as language and attention. Tracking the trajectory of neural development prior to and during the developmental window when these circuits are maturing will allow for an understanding of best potential windows of intervention.
Objectives: The long term, primary objective of this protocol is to evaluate the degree to which the development and maturation of sleep patterns, with an emphasis on the relationship of those patterns to electrophysiologic signals, can predict cognitive and behavioral outcomes. Assessing participants over time will allow researchers to gain additional knowledge about the role of abnormal sleep, measured both clinically and by polysomnogram, in various childhood neuropsychiatric/ neurodevelopmental disorders and behavioral syndromes.
Study Population: The total number of participants to be enrolled will be set at N = 244 (6 months to 8 years old) and will include the following:
- Study 1: N = 90 with no known risk for neurodevelopmental disorders. These include children without identified neurodevelopmental problems who score within age-expected ranges on cognitive and behavioral screeners.
- Study 2: N = 154 children at risk for or known to have selected neurodevelopmental/neuropsychiatric disorders, based on any one or more of the following criteria:
- Enrolled in early intervention
- Getting any targeted therapies
- Neurodevelopmental or neuropsychiatric disorder
- Failed Infant Toddler Checklist (ITC) (ages 6 months 24 months)
- Failed the Early Intervention (EI) screener (>24 months)
Design: Study 1 (N = 90) and Study 2 (N = 154) use the same accelerated longitudinal design.
Outcome Measures: The primary outcome measure in Study 1 is sleep spindle activity. Study 2 has an additional primary outcome, the Vineland Adaptive Behavior (VABS) Socialization growth scale. In both studies, secondary outcome measures will include:other characteristics of sleep spindles, sleep rhythms (ultradian, circadian), macroarchitecture (stages and latencies), microarchitecture (measures of connectivity and network analyses).
Predictors include other neurodevelopmental variables, including other domain scores from the Vineland, IQ, and quantitative measurement of behavioral problems and social communicative development.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Children with a known risk | – | –Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder. |
| Children with no known risk | – | –Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders. |
Who may qualify
- Ages
- 6 months to 8 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Study Population: The total number of participants to be enrolled will be set at N = 244 (6 months to 8 years old) and will include the following: 1) Study 1: N = 90 with no known risk for neurodevelopmental disorders. These include children without identified neurodevelopmental problems who score within age-expected ranges on cognitive and behavioral screeners. 2) Study 2: N = 154 children at risk for or known to have selected neurodevelopmental/neuropsychiatric disorders, based on any one or more of the following criteria: a) Enrolled in early intervention b) Getting any targeted therapies c) Neurodevelopmental or neuropsychiatric disorder d) Failed Infant Toddler Checklist (ITC) (ages 6 months 24 months) e) Failed the Early Intervention (EI) screener (>24 months)
Key inclusion criteria (18 listed)
- -Consent: Parent/caregiver (legal guardian) can give consent. NIH employees children are eligible to participate with the exception of NIMH employees children.
- Comments: Parents will provide consent for all minors. Verbal assent will be obtained from minors 7 years and older when applicable.
- The child is between 6 months \& 76 months at the time of enrollment for the main study.
- Comments: Prescreening assessment
- -Apnea hypopnea index (AHI) < 2/hour and no other evidence of sleep disordered breathing (SDB)
Key exclusion criteria (19 listed)
- -Meets inclusion criteria for Group B (known risk)
- Comments: Screening assessment
- -Any chronic or acute medical condition severe enough to interfere with overnight sleep study acquisition, such as a tracheotomy, uncontrolled seizure disorder, or ventilator dependency, or history of stroke or major neurologic insult. Taking any medications that is known to change sleep parameters within 2 weeks of screening polysomnogram.
- Comments: Screening assessment: Medical history
- -Any history of early intervention or diagnosis of a condition that put the child at risk for neurodevelopmental problems (e.g., genetic disorder, prenatal exposures, extreme prematurity)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sleep Spindle Activity
Time frame: ongoing
The primary outcome measure in Study 1 is sleep spindle activity. Study 2 has an additional primary outcome, the Vineland Adaptive Behavior (VABS) Socialization growth scale.
Vineland Adaptive Behavior (VABS) Socialization growth scale.
Time frame: ongoing
The primary outcome measure in Study 1 is sleep spindle activity. Study 2 has an additional primary outcome, the Vineland Adaptive Behavior (VABS) Socialization growth scale.
1 secondary outcome
Sleep Spindle Characteristics
Time frame: ongoing
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. We will use the National Sleep Research Resource (NSRR), based at Brigham and Women s Hospital, as a comprehensive data repository for the visualization, query, and analysis of sleep EEG and related physiologic parameters, neurodevelopmental and demographic data. Most medical and sleep data will be stored using NSRR. All data shared with NSRR will be coded. Samples and data for genomic analyses will be shared with Baylor College of Medicine and they will also be shared with the NIMH Repository \& Genomics Resource (NRGR). Coded data from this study for all child participants will also be submitted to the NIH sponsored National Database for Autism Research (NDAR). Data and samples may also be shared with collaborating laboratories at NIH or outside of NIH and/or submitted to NIH-designated repositories and databases if consent for sharing was obtained. Repositories receiving data and/or samples from this protocol may be open-access or restricted access.
Related trials for Healthy Children
Not yet recruiting
Leveraging Families to Promote Healthy Socio-Emotional Development in Children
Child Development, Parents
RecruitingPhase 3
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
Pneumococcal Disease
Active, not recruitingPhase 1
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
Pneumococcal Disease
Recruiting
Evaluating the Effects of an Electrical Stimulator on Improving the Walking Ability of Children With Cerebral Palsy
Cerebral Palsy Children, Healthy Adults
RecruitingObservational study
Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A Vaccine
Hepatitis A
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ashura W Buckley, M.D. principal investigator
National Institute of Mental Health (NIMH)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy Children and Children With Neurodevelopmental Disorders, run by National Institute of Mental Health (NIMH) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sleep Spindle Activity (time frame: ongoing). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.